All HHS Contracts — August 12, 2026

Palmetto GBA's $212.5M CMS contract has only $14.6M outlaid over 16 years, a 93% gap between obligated and disbursed funds, raising questions about current execution or funding flow.

Roche's $183.8M BARDA contract is cost-no-fee, meaning no profit margin, reducing the financial impact of this 12-year biodefense R&D award despite its size.

The Palmetto GBA contract ends September 2024 with no options, creating a near-term re-compete event that could disrupt a 16-year incumbent relationship.

Palmetto GBA's CMS contract shows a massive gap between $212.5M obligated and only $14.6M outlaid, indicating potential under-execution or delayed funding that could impact revenue recognition.

Palmetto GBA's contract performance is concentrated in Columbia, SC, its headquarters, creating single-location operational risk.

Roche's BARDA contract is cost-no-fee, meaning no profit contribution, limiting the financial benefit of this $183.8M award despite its long duration.

If Palmetto GBA wins a follow-on CMS contract after September 2024, it would signal a durable competitive moat in Medicare administrative services, potentially supporting revenue growth.

Roche could see scope expansion if BARDA exercises options on its 12-year biodefense R&D contract, though the cost-no-fee structure limits profit upside.

Both HHS contracts show low outlay-to-obligation ratios, suggesting that large award values may not translate to near-term revenue for contractors, particularly in administrative and R&D programs.

BARDA's cost-no-fee contract with Roche highlights that biodefense R&D funding is stable but offers limited margin expansion for contractors, reducing the investment appeal of such awards.

{"entity" => "Palmetto GBA, LLC", "reason" => "Its $212.5M CMS contract expires September 2024 with only $14.6M outlaid, creating re-compete risk and potential revenue disruption.", "trigger" => "CMS re-compete award announcement or contract extension"}

{"entity" => "Hoffmann-La Roche Inc.", "reason" => "Its $183.8M BARDA contract is cost-no-fee, limiting profit, but option exercises could signal program expansion.", "trigger" => "BARDA option exercise announcements for medical countermeasures"}